We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$27.2B
1-Year Est. Return
43.16%
This Fund
S&P 500
This Quarter
Est. Return
-3.12%
1 Year Est. Return
+43.16%
3 Year Est. Return
+177.72%
5 Year Est. Return
+262.7%
10 Year Est. Return
+1,121.27%
AUM
$19.3B
AUM Growth
-$1.05B
(-5.2%)
Cap. Flow
-$77.1M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
26.03%
Holding
1,444
New
138
Increased
405
Reduced
531
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$224M |
| 2 |
Brown-Forman Class B
BF.B
|
+$140M |
| 3 |
UnitedHealth
UNH
|
+$132M |
| 4 |
Monolithic Power Systems
MPWR
|
+$108M |
| 5 |
Oracle
ORCL
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$134M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 3 |
Micron Technology
MU
|
+$122M |
| 4 |
Pfizer
PFE
|
+$120M |
| 5 |
Microsoft
MSFT
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.43% |
| 2 | Healthcare | 14.49% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
WaFd
WAFD
$2.81B
| $457K | ﹤0.01% |
15,244
-13,865
| -48% | -$449K |
|
952
KRONOS Worldwide
KRO
$961M
| $453K | ﹤0.01% |
48,538
-87,295
| -64% | -$1.28M |
|
953
Southern Missouri Bancorp
SMBC
$853M
| $452K | ﹤0.01% |
8,858
-16,120
| -65% | -$824K |
|
954
Editas Medicine
EDIT
$442M
| $446K | ﹤0.01% |
36,453
+387
| +1% | +$6.03K |
|
955
Curtiss-Wright
CW
$26.1B
| $443K | ﹤0.01% |
3,186
-350
| -10% | -$49.7K |
|
956
Roblox
RBLX
$25.8B
| $443K | ﹤0.01% |
12,364
-13,435
| -52% | -$556K |
|
|
AVDX
957
DELISTED
AvidXchange
AVDX
| $440K | ﹤0.01% |
52,235
| – | – |
|
958
Vishay Intertechnology
VSH
$5.28B
| $439K | ﹤0.01% |
+24,655
| New | +$481K |
|
|
PWSC
959
DELISTED
PowerSchool Holdings, Inc.
PWSC
| $438K | ﹤0.01% |
26,218
-21,959
| -46% | -$355K |
|
960
Radian Group
RDN
$4.89B
| $437K | ﹤0.01% |
22,642
+890
| +4% | +$19K |
|
961
Primerica
PRI
$9.54B
| $436K | ﹤0.01% |
3,535
-1,000
| -22% | -$127K |
|
962
nVent Electric
NVT
$27.6B
| $433K | ﹤0.01% |
+13,710
| New | +$458K |
|
963
Aflac
AFL
$60.6B
| $430K | ﹤0.01% |
7,645
+2,836
| +59% | +$167K |
|
964
Karyopharm Therapeutics
KPTI
$44.2M
| $429K | ﹤0.01% |
5,244
+3,999
| +321% | +$299K |
|
965
Pacira BioSciences
PCRX
$955M
| $426K | ﹤0.01% |
8,002
| – | – |
|
966
Shutterstock
SSTK
$206M
| $425K | ﹤0.01% |
8,476
-460
| -5% | -$26.4K |
|
967
Biglari Holdings Class B
BH
$1.23B
| $423K | ﹤0.01% |
3,656
-1,281
| -26% | -$160K |
|
|
FITB
968
Fifth Third Bancorp
FITB
$52.5B
| $423K | ﹤0.01% |
+13,242
| New | +$456K |
|
969
Eaton
ETN
$176B
| $422K | ﹤0.01% |
3,164
+973
| +44% | +$136K |
|
970
Fate Therapeutics
FATE
$310M
| $422K | ﹤0.01% |
18,828
+1,247
| +7% | +$36K |
|
|
HNGR
971
DELISTED
Hanger Inc.
HNGR
| $419K | ﹤0.01% |
22,407
-31,299
| -58% | -$555K |
|
972
Stewart Information Services
STC
$2.04B
| $418K | ﹤0.01% |
9,577
-500
| -5% | -$25.5K |
|
973
WD-40
WDFC
$3.12B
| $418K | ﹤0.01% |
2,377
-943
| -28% | -$176K |
|
974
Kimberly-Clark
KMB
$36.6B
| $417K | ﹤0.01% |
3,707
+1,826
| +97% | +$237K |
|
975
Voya Financial
VOYA
$9.09B
| $414K | ﹤0.01% |
6,843
-2,100
| -23% | -$128K |
|
Similar funds
FDCDDQ
TWC
WP
N
PCH
VAI
Los Angeles Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Los Angeles Capital Management held 1,444 positions worth $19.3B, down 5.2% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Los Angeles Capital Management's Q3 2022 filing shows 138 new, 405 increased, 531 reduced and 234 closed positions. Its largest new stake was Neurocrine Biosciences: 791,966 shares worth $84.1M. The largest sale was Alphabet (Google) Class C, an estimated $134M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- Los Angeles Capital Management's largest Q3 2022 buy was Neurocrine Biosciences: 791,966 shares worth $84.1M.
- Los Angeles Capital Management added most to Broadcom in Q3 2022, an estimated $224M increase.
- Los Angeles Capital Management's biggest Q3 2022 reduction was Alphabet (Google) Class C, cutting an estimated $134M.
- Los Angeles Capital Management fully exited D.R. Horton in Q3 2022, selling an estimated $37.1M.
- Los Angeles Capital Management's ten largest holdings make up 26% of its $19.3B portfolio in Q3 2022.
- Los Angeles Capital Management opened 138 new positions and closed 234 in Q3 2022.
- Los Angeles Capital Management's portfolio value fell 5.2% quarter-over-quarter to $19.3B.
Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.